One of our favorite bio-celebrities is enlarging his CV with a new job position. The German-Canadian Chris Viehbacher will run the billionaire Gurnet Point Capital fund, owned by the Swiss magnate Ernesto Bertarelli.

If Chris Viehbacher felt disappointed after being dumped from Sanofi, at least he didn’t lose his pharma thrill. Recently, however, the business man steped a bit further aside from the labs since he is now focusing on healthcare investments. In March, Viehbacher joined PureTech Ventures‘ Board of directors, a Boston-based company that raised about €150M in an IPO on the London exchange market earlier this month.

Now, the former CEO of Sanofi has added another job to his prolific career. Swiss billionaire Ernesto Bertarelli has hired Viehbacher to run Gurnet Point Capital fund. The entrepreneur will lead the fund’s global investment strategy, with an initial allocation of €1.8Bn exclusively dedicated to life sciences.

ADVERTISEMENT

Viehbacher will continue being headquartered in Boston, his beloved city from where he tried to manage the largest French pharma. From this enviable location, the businessman will stroll around the world, searching for innovative companies to invest in. Viehbacher will be the brain and the expertise behind the investment vehicle of Bertarelli family, experts of the pharma industry which sold Serono to the German Merck for €10,6Bn in 2006.

With his new position, Chris Viehbacher will have carte blanche without needing to deal with angry Sanofi board members or French politicians. The entrepreneur could then, focus on the search of groundbreaking innovations that can take benefit from the biotech bubble.

Previous post

Will Boehringer Ingelheim win the race for anticoagulants?

Next post

DBV Technologies to cure Peanut allergy

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.